Study of new drug efficacy index and usefulness of enoxaparin sodium in patients with esophageal cancer
Not Applicable
- Conditions
- esophageal cancer
- Registration Number
- JPRN-UMIN000014623
- Lead Sponsor
- Gifu University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with a history of hypersensitivity to heparin derivative (1) or heparin (Bleeding, such as intracranial hemorrhage, retroperitoneal bleeding, in other vital organs) patients who have (2) bleeding (3) acute endocarditis patients Renal failure (4) severe (creatinine clearance less than 30mL/min) Patients with a history (5) heparin-induced thrombocytopenia (HIT) (6) Other, patients attending physician was deemed inappropriate for participation in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of leg vein thrombosis, D-dimer, fibrin monomer complex (FMC), the anti-factor Xa activity
- Secondary Outcome Measures
Name Time Method